Login to Your Account

In The Clinic NEWS

What one analyst characterized as a "weird" placebo response in one patient was enough to skew the results for Rigel Pharmaceuticals Inc.'s second of two double-blind studies in its FIT phase III program with fostamatinib.

Theravance Biopharma Inc. and Mylan NV reported that revefenacin, a nebulized LAMA for COPD, met the primary endpoints in twin phase III studies.

LONDON – The first randomized control trial investigating the effect of switching patients from the anti-TNF alpha antibody Remicade to a biosimilar version of infliximab did not show any difference between the two.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: